SynthesisFrontiers in pharmacology2026
Efficacy and safety of jinlida granule in the treatment of diabetic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic kidney disease (DKD), a major microvascular complication of diabetes, represents the leading cause of end-stage renal disease globally. Jinlida Granule (JLD), a multi-botanical Traditional Chinese Medicine preparation, has shown potential in type 2 diabetes management; however, a comprehensive systematic evaluation of its efficacy and safety specifically for DKD is lacking. Objective: To systematically evaluate the efficacy and safety of JLD for DKD through a meta-analysis. Methods: We conducted a systematic search of Chinese and English databases and clinical trial registries for randomized controlled trials (RCTs) on JLD for DKD from inception to 9 October 2025. Two researchers independently performed literature screening, data extraction, and quality assessment using the Cochrane Risk of Bias (RoB) 2 tool. Meta-analysis was conducted with a random-effects model using STATA 15.0 and Review Manager 5.4. Subgroup and sensitivity analyses were performed. Results: Twelve RCTs involving 1,341 patients were included. JLD was associated with significant reductions in serum creatinine (MD -30.54 μmol/L, 95% CI -37.61 to -23.47; I Conclusion: Current evidence suggests that adjunctive JLD may provide multifaceted clinical benefits for DKD patients, with a comparable safety profile. However, these findings should be interpreted cautiously given the moderate to high risk of bias and considerable heterogeneity. Well-designed, large-scale RCTs are required. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251178318, identifier [CRD420251178318].
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.